Kennedy Institute of Ethics Journal

University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Retrieved on: 
Thursday, May 11, 2023
Partnership, Probability, Drug development, University, TNF, IBD, Adalimumab, Genomics, Antibody, Autoimmunity, Ulcerative colitis, Inflammatory bowel disease, Kennedy Institute, Crohn's disease, Patient, Clinical research, Immune-mediated inflammatory diseases, Kennedy, Kennedy Institute of Ethics Journal, Synthetic biology, Pharmaceutical industry, Vaccine, Rheumatology

It takes an average of ten years and costs more than $1 billion to bring a new drug to market.

Key Points: 
  • It takes an average of ten years and costs more than $1 billion to bring a new drug to market.
  • Absci will use generative AI models with The Kennedy Institute’s genomics datasets to identify novel antibodies from patients with exceptional immune responses to inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
  • Then, using its reverse immunology approach, Absci will computationally re-assemble antigen-antibody pairs as promising potential starting points for drug development.
  • Absci and The Kennedy Institute will work together to accelerate the discovery and development of other promising drug targets and therapies.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Retrieved on: 
Thursday, February 16, 2023
Trial of the century, Lead, HPV, Cue, Cell signaling, Head, Selective, Nature, Patient, Signal transduction, University, Research, Modes of toxic action, Concept, Poster, Kennedy Institute, Kennedy Institute of Ethics Journal, Vaccine

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.

Key Points: 
  • The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.
  • “The data continue to support the differentiated mechanism of action of Cue Biopharma’s Immuno-STAT CUE-100 series of biologics, by uniquely mimicking the natural process of immune synapse formation,” said Jesusa Capera-Aragones, Ph.D., post-doctoral researcher, Dustin laboratory of the Kennedy Institute at the University of Oxford.
  • “By simultaneously presenting a targeted antigen and the immunostimulatory molecule IL-2, Cue Biopharma’s biologics enable the specific and simultaneous engagement of IL-2 and T cell receptors, as it would occur in nature.
  • Dr. Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, added “We are very pleased with the research and collaboration with Dr. Dustin’s laboratory of the Kennedy Institute at the University of Oxford.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

Retrieved on: 
Tuesday, February 15, 2022
University of Oxford, Nuffield Orthopaedic Centre, Â, Lead, Drug Quality and Security Act, Tumor microenvironment, CUE, Board, Regulatory T cell, COVID-19, Selective, Wellcome Trust Principal Research Fellow, Lists of diseases, Securities Act of 1933, Risk, Moscone Center, Infection, Patent, Financial condition report, Research, Result, Kennedy Institute of Ethics Journal, Kennedy Institute, Nuffield Department of Population Health, Analysis, Nasdaq, Board of directors, Policy, GLOBE, Drug development, APC, Conversation, Patient, Autoimmune disease, Form 10-Q, Cancer, Food, NHS, Forward-looking statement, University, Annual report, Securities Exchange Act of 1934, FDA, PMHC cellular microarray, TCR, Pharmaceutical industry, Vaccine, Veterinary medicine, Rheumatology

Cue Biopharma entered into a strategic research collaboration with Dr. Michael Dustin and the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series biologics.

Key Points: 
  • Cue Biopharma entered into a strategic research collaboration with Dr. Michael Dustin and the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series biologics.
  • The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules.
  • This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.